Results 181 to 190 of about 1,963 (217)
Some of the next articles are maybe not open access.
Journal of Pharmaceutical Sciences, 2008
A precipitation process is used to produce combined particles consisting of two antiasthmatic drugs: salmeterol xinafoate and fluticasone propionate. To control the crystallisation of these particles, a micromixer is used to mix solvent and antisolvent flow.
Regina, Westmeier, Hartwig, Steckel
openaire +2 more sources
A precipitation process is used to produce combined particles consisting of two antiasthmatic drugs: salmeterol xinafoate and fluticasone propionate. To control the crystallisation of these particles, a micromixer is used to mix solvent and antisolvent flow.
Regina, Westmeier, Hartwig, Steckel
openaire +2 more sources
Thermal Analysis of Trace Levels of Polymorphic Impurity in Salmeterol Xinafoate Samples
Pharmaceutical Research, 2003To quantify trace levels of polymorphic impurity in two salmeterol xinafoate (SX) Form I samples: granular SX (GSX) produced by fast-cooling crystallization and micronized SX (MSX) prepared from GSX by micronization.SX-I and SX-II produced by solution enhanced dispersion by supercritical fluids (SEDS) were the reference polymorphs (100% pure) used for ...
Tong, HHY +3 more
openaire +3 more sources
Journal of Pharmaceutical Sciences, 2005
In our previous studies, surface analysis by inverse gas chromatography (IGC) at infinite dilution (zero coverage) was performed on four salmeterol xinafoate (SX) powdered samples, viz, two supercritical CO2-processed Form I (SX-I) and Form II (SX-II) polymorphs, a commercial granulated SX (GSX) raw material and its micronized product (MSX).
Tong, HHY +3 more
openaire +3 more sources
In our previous studies, surface analysis by inverse gas chromatography (IGC) at infinite dilution (zero coverage) was performed on four salmeterol xinafoate (SX) powdered samples, viz, two supercritical CO2-processed Form I (SX-I) and Form II (SX-II) polymorphs, a commercial granulated SX (GSX) raw material and its micronized product (MSX).
Tong, HHY +3 more
openaire +3 more sources
Journal of Pharmaceutical Sciences, 2009
Direct crystallization of active pharmaceutical ingredient (API) particles in the inhalable size range of 1-6 microm may overcome surface energization resulting from micronization. The aerosolization of fluticasone propionate (FP) and salmeterol xinafoate (SX) microcrystals produced by aqueous crystallization from poly(ethylene glycol) solutions was ...
Darragh, Murnane +2 more
openaire +2 more sources
Direct crystallization of active pharmaceutical ingredient (API) particles in the inhalable size range of 1-6 microm may overcome surface energization resulting from micronization. The aerosolization of fluticasone propionate (FP) and salmeterol xinafoate (SX) microcrystals produced by aqueous crystallization from poly(ethylene glycol) solutions was ...
Darragh, Murnane +2 more
openaire +2 more sources
SALMETEROL XINAFOATE IN CHILDREN ON HIGH-DOSE INHALED STEROIDS
Pediatrics, 1996The authors conclude that salmeterol 50 µg BID is a safe, convenient, and effective modality in children whose day and night symptoms are not well controlled by 400 µg of beclomethasone per day or an equivalent of another inhaled steroid. They feel the data justify the inclusion of long-acting β-2 agents in the guidelines for the management of ...
openaire +1 more source
Agglomerate Strength and Dispersion of Salmeterol Xinafoate from Powder Mixtures for Inhalation
Pharmaceutical Research, 2006The study investigated the role of agglomeration and the effect of fine lactose size on the dispersion of salmeterol xinafoate (SX) from SX-lactose mixtures for inhalation.Particle size distributions were characterised by Malvern Mastersizer S, Aerosizer and Spraytec, and imaging conducted by scanning electron microscopy (SEM).
Handoko, Adi +5 more
openaire +2 more sources
Advances in research on inhaled drug delivery system of salmeterol xinafoate
Pharmaceutical Care and Research, 2013Salmeterol xinafoate is mainly used in the treatment of persistent asthma,chronic bronchitis and chronic obstructive pulmonary diseases.This paper made a comprehensive review of the design and research on the inhaled salmeterol xinafoate delivery system,in combination with the features of those commonly used inhaled drug dosage forms,such as inhaled ...
Hui LI +3 more
openaire +1 more source
Is β-Adrenergic-Mediated Airway Relaxation of Salmeterol Antagonized by Its Solvent Xinafoic Acid?
Chest, 1999Isolated case reports of asthmatic fatalities accompanied by the use of salmeterol have raised the question whether a paradoxical effect of salmeterol or its vehicle on the airways might contribute to these fatalities. We questioned whether salmeterol's solvent, xinafoic acid, has detrimental effects on the tone of airways or on beta-adrenoceptor ...
H, Groeben, C, Emala
openaire +2 more sources
SALMETEROL XINAFOATE AS MAINTENANCE THERAPY COMPARED WITH ALBUTEROL IN PATIENTS WITH ASTHMA
Pediatrics, 1995The use of salmeterol inhaled twice daily compared with either placebo or albuterol gave significant increases in morning and evening peak flow as well as sustained increases in FEV1, and reduced asthma symptoms throughout the day and night. Responses were similar at day 1 and week 12 and no deterioration of asthma control was observed within the study
Amy Oro, Alan Goldsobel
openaire +2 more sources
American Journal of Respiratory and Critical Care Medicine, 1997
Inhaled corticosteroids have been shown to effectively reduce large circadian fluctuations in peak expiratory flow (PEF). Salmeterol xinafoate (SLM), a new long-acting beta2-agonist being used in the treatment of nocturnal airway obstruction, has proved to be very effective in this respect as well.
Weersink, E. J. +3 more
openaire +3 more sources
Inhaled corticosteroids have been shown to effectively reduce large circadian fluctuations in peak expiratory flow (PEF). Salmeterol xinafoate (SLM), a new long-acting beta2-agonist being used in the treatment of nocturnal airway obstruction, has proved to be very effective in this respect as well.
Weersink, E. J. +3 more
openaire +3 more sources